DEFINITIVE CONTRACT
Active75F40126C00025
Department of Health and Human Services › Food and Drug Administration › FDA OFFICE OF ACQ GRANT SVCS
$325K
obligated · signed 3 months ago
BAA CONTRACT - DEVELOPMENT OF SUSCEPTIBILITY GUIDANCE FOR DAPTOMYCIN AND ENTEROCOCCUS SPECIES USING PHARMACOMETRIC APPROACHES
Performance timeline
Start
Aug 1, 2026
End
Jul 31, 2027
with all options
Loading status
This contract is likely in the recompete window
Ends with all options: Jul 31, 2027
INSTITUTE FOR CLINICAL PHARMACODYNAMICS, INC.
Contract 75F40126C00025
UEI
Z82HHPY83MC7
Parent Company
INSTITUTE FOR CLINICAL PHARMACODYNAMICS, INC.
Capabilities & Certifications
Headquarters Location
Congressional District: 20
Current Obligation
$325,000
Base + Exercised Options
$325,000
Total Ceiling Value
$325,000
Contract Type
FIRM FIXED PRICE
Multi-Year Contract
NO
NAICS
RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT NANOTECHNOLOGY AND BIOTECHNOLOGY)
PSC
SPECIAL STUDIES/ANALYSIS- SCIENTIFIC DATA
Place of Performance
Congressional District: 20
Awarding Agency
Top-tier agency
Food and Drug Administration
Sub-tier agency
FDA OFFICE OF ACQ GRANT SVCS
Office
Funding Agency
Top-tier agency
Food and Drug Administration
Sub-tier agency
FDA OFFICE OF ACQ GRANT SVCS
Office
Solicitation procedures, competition exceptions, labor standards and account totals.